




Mateon Therapeutics
Investor Relations Department
701 Gateway Blvd, Suite 210
S. San Francisco, CA 94080
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

OT: MATN

Last Trade:	0.17
Trade Time:	3:02 PM ET Jan 19, 2018
Change:	-0.02  (-10.526%)
Day Range	0.16 - 0.20
52-Week Range	0.09 - 0.89
Volume	10,230,600

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

We are committed to leveraging our intellectual property and the product development expertise of our highly experienced management team to enable vascular targeted therapy to realize its true potential and to bring much needed new therapies for orphan oncology indications to cancer patients worldwide. We have a portfolio of preclinical and clinical stage candidates focused on areas of significant unmet need that we believe can bring significant value to our shareholders.

Our common stock is traded on the OTCQX Market under the symbol "MATN".

We are head... [\(more\)](#)

Stock Quote



Press Releases [\[View all \]](#)

- Jan 8, 2018*
[Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint Inhibitors](#)
- Jan 3, 2018*
[Mateon Therapeutics to Present at the 2018 Biotech Showcase](#)
- Dec 5, 2017*
[Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor](#)
- Nov 14, 2017*
[Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results](#)
- Oct 30, 2017*
[Mateon Therapeutics Announces Updated Data from A Fifth Cohort of Phase 1b Study of OXi4503 in Acute Myeloid Leukemia](#)

Financials & Filings [\[View all \]](#)

- Mar 30, 2017*
[Annual Report \(10-K\)](#)
- Apr 26, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 14, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 2, 2017*
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)